INmune Bio (INMB) News Today $4.56 -0.15 (-3.18%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period INmune Bio, Inc.: INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's DiseaseNovember 14, 2024 | finanznachrichten.deInmune Bio’s Innovative Alzheimer’s Treatment Approach Earns ‘Buy’ Rating from AnalystNovember 14, 2024 | markets.businessinsider.comINmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's DiseaseNovember 14, 2024 | markets.businessinsider.comINmune Bio announces enrollment of 208 patients in Phase 2 trial of early ADNovember 14, 2024 | markets.businessinsider.comINmune Bio holds an investor and analyst webinarNovember 8, 2024 | markets.businessinsider.comInmune Bio’s Promising Pipeline and Financial Stability Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comINmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)November 4, 2024 | finance.yahoo.comINmune Bio (NASDAQ:INMB) Announces Quarterly Earnings ResultsINmune Bio (NASDAQ:INMB - Get Free Report) posted its earnings results on Thursday. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 121.57% and a negative net margin of 26,333.59%. During the same period last year, the business earned ($0.48) EPS.November 3, 2024 | marketbeat.comINmune Bio, Inc. (NASDAQ:INMB) Q3 2024 Earnings Call TranscriptNovember 2, 2024 | msn.comInmune Bio Reports Increased Losses Amid Financing EffortsNovember 2, 2024 | markets.businessinsider.comBuy Rating on Inmune Bio: Promising EMACC Endpoint and Innovative XPro Drug in Alzheimer’s TreatmentNovember 2, 2024 | markets.businessinsider.comINmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...November 2, 2024 | finance.yahoo.comINmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business UpdateOctober 31, 2024 | globenewswire.comShort Interest in INmune Bio, Inc. (NASDAQ:INMB) Increases By 5.6%INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 2,830,000 shares, an increase of 5.6% from the September 30th total of 2,680,000 shares. Based on an average daily trading volume, of 225,300 shares, the short-interest ratio is presently 12.6 days.October 31, 2024 | marketbeat.comINmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look ForOctober 30, 2024 | finance.yahoo.comINmune Bio to host webinar on cognitive testing using EMACC, CDR-SBOctober 29, 2024 | markets.businessinsider.comINmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SBOctober 28, 2024 | globenewswire.comHighbridge Capital Management's Strategic Acquisition of INmune Bio Inc SharesOctober 25, 2024 | finance.yahoo.comINmune Bio (INMB) Set to Announce Quarterly Earnings on ThursdayINmune Bio (NASDAQ:INMB) will be releasing earnings after the market closes on Thursday, October 31, Zacks reports.October 25, 2024 | marketbeat.comINmune Bio announces publication of XPro1595 data in Cell ReportsOctober 25, 2024 | markets.businessinsider.comINmune Bio (INMB)October 24, 2024 | es.investing.comINmune Bio Says XPro1595 Promotes Remyelination, Key for Central Nervous System DiseasesOctober 24, 2024 | marketwatch.comINmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes RemyelinationOctober 24, 2024 | globenewswire.comINmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024October 24, 2024 | globenewswire.comAlliance Global Partners Initiates Coverage of INmune Bio (INMB) with Buy RecommendationOctober 22, 2024 | msn.comINmune Bio (NASDAQ:INMB) Earns Buy Rating from Analysts at Alliance Global PartnersAlliance Global Partners started coverage on INmune Bio in a report on Monday. They issued a "buy" rating and a $20.00 price objective on the stock.October 21, 2024 | marketbeat.comINmune Bio, Inc. (NASDAQ:INMB) Sees Large Decrease in Short InterestINmune Bio, Inc. (NASDAQ:INMB - Get Free Report) was the target of a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 2,680,000 shares, a decline of 15.2% from the September 15th total of 3,160,000 shares. Based on an average daily trading volume, of 218,600 shares, the short-interest ratio is currently 12.3 days.October 14, 2024 | marketbeat.comINmune Bio Inc. to Participate in the Maxim Healthcare Virtual SummitOctober 11, 2024 | globenewswire.comINmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising CostsOctober 10, 2024 | finance.yahoo.comInmune Bio (INMB) Receives a Buy from ScotiabankOctober 1, 2024 | markets.businessinsider.comINmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss Acquires 10,000 SharesOctober 1, 2024 | insidertrades.comINmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's DiseaseOctober 1, 2024 | markets.businessinsider.comCVI Holdings LLC Purchases New Position in INmune Bio, Inc. (NASDAQ:INMB)CVI Holdings LLC purchased a new stake in shares of INmune Bio, Inc. (NASDAQ:INMB - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 596,372 shares of the company's stock, valued at approximately $5,260,000. INmunSeptember 28, 2024 | marketbeat.comRaymond James Initiates Coverage of INmune Bio (INMB) with Outperform RecommendationSeptember 28, 2024 | msn.comAchieve, INmune, Lenz gain on bullish initiations from Raymond JamesSeptember 27, 2024 | msn.comBuy Rating Affirmed for Inmune Bio on Promising INKmune Therapy DataSeptember 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inmune Bio on Promising Clinical Data and Market PotentialSeptember 27, 2024 | markets.businessinsider.comINmune Bio (NASDAQ:INMB) Coverage Initiated by Analysts at Raymond JamesRaymond James started coverage on shares of INmune Bio in a report on Friday. They set an "outperform" rating and a $18.00 target price on the stock.September 27, 2024 | marketbeat.comINKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing CohortSeptember 26, 2024 | globenewswire.comInmune Bio CFO acquires $49k in company stockSeptember 19, 2024 | investing.comInmune Bio Earns ‘Buy’ Rating on Strategic Alzheimer’s Drug Development and Solid Financial FootingSeptember 19, 2024 | markets.businessinsider.comInmune Bio’s Promising AD Treatment Approach Merits Buy Rating, Analyst SaysSeptember 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Inmune Bio (INMB) and Zevra Therapeutics (ZVRA)September 18, 2024 | markets.businessinsider.comINmune Bio Announces Data From AD02 Phase II Alzheimer's TrialSeptember 17, 2024 | markets.businessinsider.comINmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB EndpointsSeptember 17, 2024 | globenewswire.comInsider Buying: INmune Bio, Inc. (NASDAQ:INMB) CFO Purchases 7,690 Shares of StockSeptember 17, 2024 | insidertrades.comINmune Bio Shares Fall After $13M Direct Offering PricesSeptember 13, 2024 | marketwatch.comINmune Bio stock dips on $13M securities offeringSeptember 13, 2024 | msn.comINmune Bio, Inc.'s (NASDAQ:INMB) top owners are individual investors with 44% stake, while 23% is held by institutionsSeptember 13, 2024 | finance.yahoo.comINmune Bio Announces $13.0 Million Registered Direct OfferingSeptember 13, 2024 | globenewswire.com Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. INMB Media Mentions By Week INMB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INMB News Sentiment▼0.220.46▲Average Medical News Sentiment INMB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INMB Articles This Week▼22▲INMB Articles Average Week Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cidara Therapeutics News Today X4 Pharmaceuticals News Today Fortress Biotech News Today Mustang Bio News Today Verve Therapeutics News Today Larimar Therapeutics News Today Canopy Growth News Today 4D Molecular Therapeutics News Today Akebia Therapeutics News Today KalVista Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INMB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
